← Back to Search
Higher Serum Total Cholesterol Levels In Late Middle Age Are Associated With Glucose Hypometabolism In Brain Regions Affected By Alzheimer's Disease And Normal Aging
E. Reiman, K. Chen, J. Langbaum, Wendy Lee, C. Reschke, D. Bandy, G. Alexander, R. Caselli
Published 2010 · Computer Science, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) epsilon4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE epsilon4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE epsilon4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.
This paper references
A RATING SCALE FOR DEPRESSION
M. Hamilton (1960)
Abnormal histidine metabolism in thyrotoxicosis in man. A possible index of impaired folate function.
S. D. Mohamed (1965)
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
Effects of Human Aging on Patterns of Local Cerebral Glucose Utilization Determined by the [18F] Fluorodeoxyglucose Method
D. Kuhl (1982)
SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MEN
Michael Martin (1986)
Talairach: Co-planar stereotaxic atlas of the human brain
J. Talairach (1988)
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
R. Mahley (1988)
Decrease of frontal metabolism demonstrated by positron emission tomography in a population of healthy elderly volunteers.
E. Salmon (1991)
Serum cholesterol in young men and subsequent cardiovascular disease.
M. Klag (1993)
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
Single-day apolipoprotein E genotyping
R. Crook (1994)
Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol
D. Sparks (1994)
Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age.
A. Loessner (1995)
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
S. Haubenwallner (1995)
Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation
T. Ohm (1995)
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
E. Reiman (1996)
Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
L. Farrer (1997)
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
L. Farrer (1997)
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.
D. Snowdon (1997)
Brain infarction and the clinical expression of Alzheimer disease.
S. Mirra (1997)
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
R. Brookmeyer (1998)
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.
M. Simons (1998)
Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.
Y. Kuo (1998)
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol*
D. Howland (1998)
The role of cholesterol in the biosynthesis of beta-amyloid.
E. Frears (1999)
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
L. Refolo (2000)
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
B. Wolozin (2000)
Relationships between Cholesterol, Apolipoprotein E Polymorphism and Dementia: A Cross-Sectional Analysis from the PAQUID Study
M. Bonarek (2000)
PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE
R. M. R. Eiman (2000)
Statins and the risk of dementia
H. Jick (2000)
A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
L. Refolo (2001)
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
K. Fassbender (2001)
Cholesterol and neuropathologic markers of AD
L. Launer (2001)
Cholesterol and neuropathologic markers of AD: A population-based autopsy study
L. Launer (2001)
Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease
E. Reiman (2001)
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.
M. Kivipelto (2001)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
S. Yusuf (2002)
Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients.
J. Buxbaum (2002)
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
D. Sparks (2002)
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
G. Alexander (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J. Shepherd (2002)
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.
K. Rockwood (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
AndrewJ. S. Coats (2002)
Alzheimer disease in the US population: prevalence estimates using the 2000 census.
L. Hebert (2003)
Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease
D. Sparks (2003)
The endophenotype concept in psychiatry: etymology and strategic intentions.
I. Gottesman (2003)
Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology
M. Pappolla (2003)
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
E. Reiman (2003)
Statin therapy and risk of dementia in the elderly
G. Li (2004)
Association between Statin Use and Alzheimer’s Disease
E. Zamrini (2004)
Atorvastatin‐induced activation of Alzheimer's α secretase is resistant to standard inhibitors of protein phosphorylation‐regulated ectodomain shedding
S. Parvathy (2004)
Effects of Lovastatin and Pravastatin on Amyloid Processing and Inflammatory Response in TgCRND8 Brain
N. Chauhan (2004)
Statin therapy and risk of dementia in the elderly: a community-based prospective cohort
G. Li (2004)
Serum cholesterol and risk of Alzheimer disease
G. Li (2005)
High total cholesterol levels in late life associated with a reduced risk of dementia
M. Mielke (2005)
A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease.
A. Papassotiropoulos (2005)
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia
C. Dufouil (2005)
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
M. Schachter (2005)
Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism
E. Reiman (2005)
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate β-Amyloid-Induced Microglial Inflammatory Responses
Andrew Cordle (2005)
Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.
P. Zandi (2005)
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
D. Sparks (2005)
Statin use and the risk of incident dementia: the Cardiovascular Health Study.
T. Rea (2005)
Cholesterol in Alzheimer's disease
Leila Shobab (2005)
Serum cholesterol and risk of Alzheimer disease: a community-based cohort
J. D. Bowen (2005)
Statin use and the risk of Alzheimer’s disease: The MIRAGE Study
R. Green (2006)
Differential Effect of Statins on Risk of AD by Age, Sex, and APOE Genotype: Findings From a Community-based Prospective Cohort Study
Ge Li (2006)
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol‐Lowering Treatment (ADCLT) trial
D. Sparks (2006)
Differential effect of statins on risk of AD by age, sex and APOE genotype: findings from a community-based prospective cohort study
G. Li (2006)
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
B. Wolozin (2007)
Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study.
R. Stewart (2007)
Serum cholesterol changes after midlife and late-life cognition
A. Solomon (2007)
Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of β2-adrenergic receptor polymorphisms
N. K. Bartels (2007)
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
G. Li (2007)
Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
C. Carlsson (2008)
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
C. Cramer (2008)
Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions
E. Reiman (2008)
Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on β-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells
J. Prasanthi (2009)
S5-01-05: Multi-center, randomized, double-blind, placebo-controlled trial of Simvastatin to slow the progression of Alzheimer's disease
M. Sano (2008)
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study
M. Haag (2008)
The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics
R. Jones (2008)
Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B12, Folate and Lipids in Patients with Alzheimer Disease
L. Li (2008)
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Z. Arvanitakis (2008)
Multi-center, randomized, double-blind, placebo-controlled trial of simvastatin to slow the progression of Alzheimer's disease
M. Sano (2008)
Cholesterolrelated genetic risk scores are associated with hypometabolism in Alzheimer'saffected brain
E. M. Reiman (2008)
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
J. Langbaum (2009)
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
E. Reiman (2009)
Brain Imaging in the Evaluation of Putative Alzheimer’s Disease-Slowing, Risk-Reducing and Prevention Therapies
E. Reiman (2009)
Imaging the aging brain
W. Jagust (2009)
An inverse association of cardiovascular risk and frontal lobe glucose metabolism
B. Kuczynski (2009)
The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease
B. Hutter-Paier (2010)
This paper is referenced by
Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum
Role of White Matter Hyperintensities and Related Risk Factors in Vascular Cognitive Impairment: A Review
Yiyi Chen (2021)
New insights into human prefrontal cortex aging with a lipidomics approach
M. Jové (2021)
Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals: The PESA Study.
M. Cortés-Canteli (2021)
Low Cholesterol Level Linked to Reduced Semantic Fluency Performance and Reduced Gray Matter Volume in the Medial Temporal Lobe
F. Yang (2020)
A Crosstalk Between Brain Cholesterol Oxidation and Glucose Metabolism in Alzheimer’s Disease
P. Gamba (2019)
Redox lipidomics to better understand brain aging and function.
R. Pamplona (2019)
Relationships between dietary nutrients intake and lipid levels with functional MRI dorsolateral prefrontal cortex activation
Huijin Lau (2018)
Brain imaging measurements of fibrillar amyloid‐β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele
Valentina Ghisays (2019)
Procyanidin B2 protects against d-galactose-induced mimetic aging in mice: Metabolites and microbiome analysis.
Ying Xiao (2018)
Concurrent Low Brain and High Liver Uptake on FDG PET Are Associated with Cardiovascular Risk Factors
Hyun-Yeol Nam (2017)
Influence of sleep duration on cortical oxygenation in elderly individuals
K. Katô (2017)
Apolipoprotein E variants and genetic susceptibility to combat-related post-traumatic stress disorder: a meta-analysis
Yang Roby (2017)
27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation
M. Ismail (2017)
Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies
Hyo Jung Choi (2017)
Amyloid Beta Peptides Affect Pregnenolone and Pregnenolone Sulfate Levels in PC-12 and SH-SY5Y Cells Depending on Cholesterol
Ozlem Gursoy Calan (2016)
Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism
H. Nielsen (2017)
Brain fluorodeoxyglucose (FDG) PET in dementia
Takashi Kato (2016)
Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: In vivo magnetic resonance study
R. Tušková (2015)
Disrupted Functional and Structural Networks in Cognitively Normal Elderly Subjects with the APOE ɛ4 Allele
Y. Chen (2015)
Lipidomics of human brain aging and Alzheimer's disease pathology.
A. Naudí (2015)
[Possibilities of modern imaging technologies in early diagnosis of Alzheimer disease].
P. Unschuld (2015)
The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies.
L. K. Ferreira (2014)
THE RELATIONSHIP BETWEEN FASTING SERUM GLUCOSE, BRAIN METABOLISM AND NEUROPSYCHOLOGICAL FUNCTIONING IN OLDER AND YOUNGER ADULTS
C. M. Burns (2014)
PET and SPECT Studies of Ageing and Cardiovascular Risk Factors for Alzheimer’s Disease
G. Busatto (2014)
Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions
S. Villeneuve (2014)
Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients.
J. Friedman (2014)
Analyses post-génomiques : étude de l'implication d'IL-33 et de BIN1 dans la physiopathologie de la maladie d'Alzheimer
A. Mounier (2013)
Interindividual variation in serum cholesterol is associated with regional white matter tissue integrity in older adults
Victoria J. Williams (2013)
Association between Dopamine D4 Receptor Polymorphism and Age Related Changes in Brain Glucose Metabolism
N. Volkow (2013)
The ABCA7 transporter, brain lipids and Alzheimer’s disease
S. Soscia (2013)
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions
C. M. Burns (2013)See more